Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for Epilepsy

Impact · against what's priced in

Biohaven receives a significant liquidity boost and risk reduction through a strategic partnership with SK Biopharmaceuticals. The deal secures $400 million in near-term non-dilutive cash and shifts the R&D costs and Knopp Biosciences liabilities ($245 million) to the partner while maintaining royalty upside.

BHVN+0.70

No priced-in read yet